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Abstract
Duchenne muscular dystrophy is a complex and severe orphan disease. It 
develops when the organism lacks the expression of dystrophin - a large structural 
protein. Dystrophin is transcribed from the largest gene in the human genome. At 
the moment, there is no cure available. Dozens of groups all over the world search 
for cure. Animal models are an important component of both the fundamental 
research and therapy development. Many animal models reproducing the features 
of disease were created and actively used since the late 80’s until present. The 
species diversity spans from invertebrates to primates and the genetic diversity 
of these models spans from single mutations to full gene deletions. The models 
are often non-interchangeable; while one model may be used for particular drug 
design it may be useless for another. Here we describe existing models, discuss their 
advantages and disadvantages and potential applications for research and therapy 
development.
Keywords: Duchenne muscular dystrophy, DMD, dystrophin, animal models, mdx, 
genome editing, exon-skipping, gene therapy
1. Introduction
Duchenne muscular dystrophy (DMD) was primarily described in 1834–1836 
by Neapolitan physicians Giovanni Semmola and Gaetano Conte. Dr. Guillaume 
Duchenne de Boulogne made a significant contribution to the description of the 
disease in 1860s [1]. DMD is considered a rare, or orphan, disease but it is definitely 
one of the most frequent among muscular dystrophies. About one male in 3500 is 
diagnosed with DMD. DMD is an X-linked recessive disease so women are affected 
with a frequency of 1 case per 50 million [2–4]. Many attempts of various groups 
and organizations are set towards the search for the cure. Different strategies such 
as genome editing, replacement therapy, anti-inflammatory and antioxidative drug 
treatment are developed [5]. These therapies target different components of an 
extremely complex scheme of DMD pathogenesis. So animal models are important 
for study of the disease, research and development of the therapies. Many animal 
models were created or, in some cases, adapted from natural sources.
It is important to understand the mechanism of DMD pathogenesis and pro-
gression in order to discuss origins, purposes and potential uses of animal disease 
models. DMD develops when the organism lacks dystrophin expression. Dystrophin 
is encoded by the largest gene in the genome (DMD) that consists of more than 2.3 
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megabases (Mb). The gene contains 7 promoters and two polyadenylation signal 
sequences which orchestrate expression of 17 known isoforms. Three large isoforms 
are produced by three distant promoters. These isoforms are brain isoform Dp427c, 
muscle isoform Dp427m and Purkinje isoform Dp427p [6]. Each of them consists of 
79 exons which include the first unique exon and 78 common exons. Several smaller 
isoforms are operated by 4 internal promoters and some of them have alternatively 
spliced variants. These isoforms are retinal Dp260, Dp140 which is prevalent in 
central nervous system (CNS) and kidney, Dp116 which is expressed in Schwann 
cells and ubiquitously expressed Dp71 and Dp40 [6, 7]. Muscle isoform Dp427m is 
the most characterized and widely studied due to its crucial role in DMD manifesta-
tion. Most of the mutations that lead to DMD progression are large insertions, exon 
deletions or duplications which lead to the shift of the reading frame in the Dp427m 
[8]. Usually these mutations produce preliminary stop codon leading to the com-
plete absence of the protein [8]. Point mutations (deletions, insertions or substitu-
tions) are responsible for a small portion of all DMD cases [8]. Other isoforms are 
studied less. The deficiency of most of them is usually linked to CNS and behavioral 
disorders while Dp260 deficiency is linked to retinal impairment [6, 7].
Muscle dystrophin is a very complicated molecular machine. The function of 
muscle dystrophin is formation of dystrophin-associated protein complex (DAPC) 
and absorption of mechanical tensions which occur due to muscle constriction 
[9]. Muscle dystrophin is 427 kDa protein that consists of 3685 amino acids [10]. 
The protein is usually divided in four functional and structural superdomains. The 
N-terminal superdomain consists of two calpain-homology domains and provides 
binding of the protein to actin. The second superdomain is called rod domain. It is 
the largest domain that includes 24 spectrin-like repeats and 4 unstructured hinge 
domains. It acts as a spring that adsorbs mechanical tensions. The third superdo-
main (referred to as cysteine-rich domain, or CR) includes WW-motif, two EF 
motifs and ZZ-motif. This domain binds dystrophin to the sarcolemmal proteins 
being the central driver of DAPC formation. C-terminal domain binds to several 
proteins performing mostly signal functions [10].
DAPC is located in sarcolemma and provides the linkage between dystrophin 
and external proteins such as laminin and collagen. The complex includes ɑ- and 
β-dystroglycans, ɑ-,β-, 𝛾-,δ-,ε-sarcoglycans which interact with CR domain of 
dystrophin; and dystrobrevin, α1, β1, and β2-syntrophins, neuronal nitric oxide 
synthase (nNOS) and several other proteins which interact with C-terminal 
domain. The deficiency of these proteins also induces several pathologies such as 
limb-girdle muscular dystrophy, myotonia and some others [9].
The loss of dystrophin leads to several consequences. The initial one is the loss of 
membrane integrity and toughness. This causes membrane damage during muscle 
contractions and consequent membrane leakage. The homeostasis of extra- and 
intracellular components (calcium ions being the most important of all) is disrupted. 
This leads to calcium signaling imbalance, mitochondrial dysfunction (as mitochon-
dria acts as calcium depo), proinflammatory and apoptotic signaling activation and 
other damaging consequences [11]. Finally, this results in muscle cell death and its 
replacement by new muscle cells originating from satellite predecessor cells that 
finally leads to depletion of the pool of satellite cells. Damaged and regenerating 
muscle tissue is characterized by central nuclei. The fraction of central nucleated 
myofibers is a quantitative marker of DMD progression and therapeutic treatment 
[12]. Normal muscular tissue is also replaced by connective tissue (fibrosis) and 
adipose tissue in addition to regeneration. Neutrophil and macrophage infiltration 
also accompanies the disease progression [13].
The first symptoms of DMD usually arise at the age of 16–18 months. The chil-
dren may experience issues with walking, running or rising, toe walking or Gower’s 
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sign. At the age of 2–3 years old the muscles of lower limbs begin to degrade. The 
children suffer from extensive weakness and obtain specific gait patterns. Scoliosis 
and flexion contractures of the limbs also develop in DMD patients. At the age of 
10–12 years old children begin to use a wheelchair. Later, at 14 y.o., some patients 
develop dilated cardiomyopathy and arrhythmia. Patients usually die at 20 years 
due to heart failure or respiratory distress in absence of proper treatment. Female 
carriers do not suffer from severe symptoms; they usually have cardiomyopathy, 
mild respiratory issues, creatine kinase (CK) level enhancement and pseudo hyper-
trophy of the backside of the shin [14].
If any suspicious symptoms are observed CK level estimation is the first 
diagnostic procedure. This is a cheap and fast but not selective test as CK growth 
is a symptom of various muscle and nonmuscle (i.e. liver) diseases. So further 
diagnostics is required. If the CK is elevated the screening for exon deletion or 
duplication should be performed. About 30% of mutations may not be identified by 
these techniques (multiplex ligation-dependent probe amplification or comparative 
genomic hybridisation array) and full sequencing of the gene is required. The muta-
tion location and character may help to predict the type and severity of the disease. 
If the mutation is still unidentified the muscle biopsy sample should be tested for 
dystrophin protein presence by immunohistochemistry or western blot [14].
In some cases, mutations in DMD gene do not lead to reading frame shift or do 
not cause severe instability or protein dysfunction. If the function of the protein 
is slightly affected the milder form of muscular dystrophy develops. This disease 
is referred to as Becker muscular dystrophy (BMD). BMD is characterized by a 
very wide spectrum of symptoms. In some cases disease may be almost as severe 
as DMD while in other cases it may develop comparatively mild phenotype [15]. In 
1990 a patient with a large part (>50%) of the DMD gene deletion was discovered 
[16]. The patient was active at 61-year-old and demonstrated mild myodystrophy 
phenotype further described as BMD. The analysis of the mutant gene and its prod-
uct revealed extremely valuable data on the mechanism of dystrophin molecular 
action. The deletion of the part of the gene did not lead to reading frame shift and 
functional protein was expressed. This protein lacked most of the rod domain while 
N-terminal, cysteine rich and C-terminal domains remained intact. Obviously the 
rod domain which is the largest part of the protein may be truncated without com-
plete function loss. The second important outcome is the frameshift rule formula-
tion. The restoration of the reading frame may lead to the synthesis of truncated but 
still partly functional protein and shift the DMD type to BMD type. These findings 
set the initial point for development of several antiDMD therapies [5].
Currently no ultimate cure for DMD exists. Several treatment strategies are 
currently applied and many approaches are waiting for approval or being devel-
oped [5]. Most of the approved treatments target the farther consequences of dys-
trophin loss [5, 11]. Glucocorticosteroids suppress fibrosis and inflammation and 
mechanical ventilation helps patients with respiratory deficits. Anti-inflammatory 
and antioxidant drugs are also used or being tested [11]. But these approaches do 
not target the primary issue and are capable of lengthening the lifespan for about 
a decade. Several more complex approaches are now being developed. One of the 
most promising candidate therapies is the gene replacement therapy [17]. The idea 
is the delivery of a shortened but still functional gene copy to the muscles lacking 
its natural variant. The delivery may be provided via various types of vectors such 
as viral vectors, nanoparticles or even plasmids [18]. Several difficulties compli-
cate the path to success. These are extremely high research and production costs, 
immune response and comparatively large size of the protein and correspond-
ing genetic construct. Another class of therapies being developed is restoration 
of the reading frame [19]. This may be achieved by introduction of antisense 
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oligonucleotide, genome editing or some other techniques. The next class of 
therapies is utrophin modulation. Utrophin is an autosomal paralog of dystrophin 
which shares almost similar domain organization and high sequence correlation 
with dystrophin. In embryonic muscles utrophin localizes similarly to dystrophin 
and performs the same functions. In muscles utrophin is replaced by dystrophin 
in early childhood and in adults it is present in such non-muscle tissues as renal 
epithelia. In the adult organism utrophin expression is extremely low. In the case 
of dystrophin deficiency the expression of utrophin starts to increase but its level 
is still insufficient for dystrophin replacement in humans. Several approaches such 
as transcription modulators may potentially increase utrophin expression and slow 
down the disease progression [20]. Interestingly, several species such as mice are 
able to increase utrophin expression to sufficient level without any modulators 
[21]. This may provide fundamental data about dystrophy compensation mecha-
nisms. However, it questions the adequacy of the DMD model based on these 
species. Other strategies include cell-based therapies which are being developed 
for a long time and interesting exosome-based approach which originated from 
cell-based one [22].
As can be seen from the above, the existing and potent strategies for DMD 
therapy include genome editing, pre-mRNA splicing and cell modification, gene 
or cell delivery, and others [5]. All of them require animal models to be tested. In 
most cases these models are not interchangeable. For example, if one develops an 
exon-skipping strategy for a rare mutation, they will need an animal model with 
a corresponding mutation. So ideally a unique model is essential for every single 
mutation (at least for most common of them). The type and location of mutation is 
also important as, despite almost all mutations lead to absence of three major iso-
forms, the presence or absence of short isoforms depends on mutation location and 
type. So different mutations on similar backgrounds may have different phenotypes 
and may be valuable both for research and drug development. Many animal (mostly 
mouse) models with different specific mutations were developed both for funda-
mental studies of the gene and protein function and role of short isoforms and for 
proof-of-concept and preclinical studies of potential therapies.
Despite mouse models of DMD being the most common due to their relative 
cheapness they possess a significant disadvantage. All dystrophin-deficient animals 
have dystrophic symptoms but the severity of them does not often correlate with the 
disease severity in DMD patients. For example the lifespan of classic mouse model 
mdx is about 80% of normal [23, 24] while the lifetime of a human with DMD is not 
more than one third of healthy. To circumvent these demerits, several other species 
were used to reproduce the phenotype of DMD in animals. These are large animal 
models (dogs, pigs, primates) or mouse models with mutations in additional genes, 
or crossbreed models. In some cases the genetic structure of these models does not 
correspond to any known DMD mutation in humans but similar phenotype makes 
them useful for studies of the disease and several symptomatic therapies.
Here we describe animal models starting from classic mdx identified in 80’s 
to the newest ones introduced in 2020. The list of model species includes species 
from such invertebrates as D. melanogaster and C. elegans to monkeys. The origin, 
genotype, phenotype and purpose of these models are very diverse. We basically 
divide the models into two large groups. Chapter 1 will focus mostly on phenotypic 
properties of the most common models, the comparison of their advantages and 
disadvantages and their use in research and drug development. Chapter 2 will focus 
on the models created for development of unique and precision therapies. These 
are mostly murine models with various spectrum of mutations suitable for targeted 
drug design such as exon skipping.
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2. Animal models to study the pathogenesis of DMD
The most widely used and well described animal model for Duchenne muscu-
lar dystrophy (DMD) research is the mdx mouse. Spontaneous X chromosome-
linked mutation arose in inbred C57BL/10 colony of mice and produced viable 
and fertile homozygous animals. Mutant mice exhibited specific features similar 
to human DMD such as elevated plasma pyruvate kinase and CK levels and 
histological lesions of skeletal muscles. Later, the nature of the mutation was 
established. Nonsense point mutation caused by a single base substitution of 
C for T within an exon 23 leads to a premature termination of the dystrophin 
translation [24]. In addition to the absence of dystrophin all proteins of the 
DAPC such as sarcoglycans, syntrophin, nNOS, dystrobrevin, α-dystroglycan 
are significantly reduced at the sarcolemma in mdx skeletal muscle [9]. The 
absence of dystrophin and destabilization of the DAPC complex are believed to 
make muscle cells susceptible to stretch-induced damage and increased intracel-
lular calcium influx. These pathological processes lead to skeletal and cardiac 
muscle degeneration [9]. Despite the absence of full-length dystrophin, mdx 
mice have mild symptoms of muscular dystrophy compared to DMD patients 
or the golden retriever muscular dystrophy (GRMD) dog model [24]. The 
pathogenesis of muscular dystrophy, physiological, biochemical and histological 
characteristics have been well studied in mdx mice of various ages. Birth body 
weight and neonatal death rates do not differ from their wild type counterparts. 
Significant histopathological abnormalities begin to be observed in mdx muscles 
at 3–4 weeks. The occurrence of extensive necrosis followed by regeneration and 
involving skeletal muscles was documented in mdx mice as young as 16–17 days 
[25]. In humans DMD is characterized by muscle hypertrophy in the early 
ages and atrophy in the late stages of disease. Contrary, in mdx mice myofibers 
pass through progressive hypertrophy from week 24 till the end of life without 
atrophy signs. Myofiber branching increased with the age and contributed to the 
hypertrophy. Aged mdx myofibers are also hypernucleated. The “extra” nuclei 
are central nuclei which highlight that the muscle undergoes continuous cycles of 
degeneration-regeneration. The estimation of synapse number indicated signifi-
cant myofiber loss in mdx mice with the age [26]. The damaged skeletal muscle 
fibers with impaired function lead to a 20–30% loss in maximum specific force 
depending on mice age. The weakness is more severe in muscles of old mdx than 
in younger mice and healthy control mice [27]. Mdx muscle also demonstrates 
high susceptibility to contraction-induced injury [28]. Except skeletal muscles 
the diaphragm is severely damaged in mdx mice showing progressive deteriora-
tion, as is also typical for affected humans [24]. Compared to the voluntarily 
moving limb muscles, diaphragm fibers in mdx mice are subjected to early 
contraction-induced membrane rupture due to continuous action in the absence 
of dystrophin [24]. Histopathological changes of mdx diaphragm start to be 
observed at 4 weeks and include myofiber degeneration, necrosis, mineralization 
and large areas of fibrosis. But in contrast to the limb skeletal muscles, which 
are constantly affected to cycles of degeneration and regeneration, diaphragm 
undergoes progressive degeneration. By 16 months of age the mdx diaphragm 
looks pale due to extensive myofiber necrosis and replacement fibrosis. Changes 
in the physiological properties of mdx diaphragm correlate to histopathological 
lesions. Another muscular organ that is affected in mdx mice as in DMD patients 
is the heart. Echocardiographic signs of cardiomyopathy arise after ~8 months 
of age, while histological evidence of interstitial cardiac fibrosis does not appear 
until about 17 months [29].
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Similar to DMD patients, mdx mice have increased levels of CK, marker of 
muscle damage, wherein CK levels were shown to increase with age, exercise, and 
male gender [30].
Since the pathogenesis of DMD in the mdx mice is genetically, biochemically 
and histologically similar to DMD patients, they have been extensively used as a 
preclinical model for DMD over the last 20 years. These mice are used to study the 
mechanisms of disease occurrence and dystrophin function, to test pharmaceuti-
cal drugs and to establish proof-of-concept for gene and cell therapy focusing on 
restoration of dystrophin expression [24, 30, 31]. The efficacy of a large number of 
pharmacological agents such as prednisone, deflazacort and other immunosuppres-
sive and anti-inflammatory drugs currently used in therapy of DMD patients was 
tested in mdx mice in preclinical trials [30]. Also mdx mice were used in preclinical 
trials of replacement gene therapy on adeno-associated viruses carrying the dystro-
phin microgene/minigene. This therapy is currently in clinical trials [17].
Although mdx mice are the most commonly used animal model for DMD, its 
main disadvantage is the mild phenotype compared to DMD patients. To enhance 
muscular dystrophy pathology a lot of animal models with a more severe pheno-
type were created. Several approaches were used to create new murine models 
with DMD symptoms: N-ethylnitrosourea (ENU) mutagenesis (mdx2Cv, mdx3Cv, 
mdx4Cv, mdx5Cv mice models), generation of humanized transgenic mice with yeast 
artificial chromosomes (YAC) (hDMD mice), CRISPR/Cas9 (Clustered Regularly 
Interspaced Palindromic Repeats/CRISPR associated protein 9) and homologous 
recombination in embryonic stem cells (different murine models with exons dele-
tion/duplication), Cre-loxP (Cre is from gene name cre that means “causes recom-
bination”; loxP is for Locus of Crossover in P1) recombination system (Dmd-null 
mice), breeding mdx mice with other backgrounds (DBA/2-mdx mice, albino-mdx 
mice, BALB/c-mdx mice, immune deficient mdx mice) or other knockout (KO) 
murine models (hDMD/mdx mice, hDMD/Dmd null mice, mdx/Cmah−/−, 
hDMD/mdx/Utrn−/−, mdx/Utrn−/−, mdx/a7−/−, mdx/MyoD−/−).
Four new mdx murine models (mdx2Cv, mdx3Cv, mdx4Cv, mdx5Cv) were generated 
with ENU chemical mutagenesis [32]. Nature of these mutations was characterized. 
It was established that mdx2Cv allele results from mutation affecting mRNA splic-
ing, and is located in the splice acceptor of intron 42 [33]. The mdx3Cv allele arises 
from a mutant splice acceptor site in intron 65 [32]. Similar to the mdx2Cv allele, the 
mdx3Cv splice acceptor mutation generates a complex pattern of aberrant splicing 
that generates multiple transcripts. But, in contrast to the mdx3cv mutation, alter-
native transcripts generated from mdx2Cv allele do not preserve the normal open 
reading frame [33]. In the case of the mdx4Cv allele, mutation is a C to T transition 
in exon 53, creating a stop codon (CAA to TAA). In the mdx5Cv allele, the dystrophin 
mRNA contains a 53 base pairs deletion and a single A to T transversion in exon 10 
which does not alter the encoded amino acid. But a new splice donor was created 
(GTGAG) that generates a frameshifting deletion in the processed mRNA [33]. 
Despite all four new mutants show elevated serum CK level and muscle pathology 
similar to original mdx mice [32], each strain of mutant mice has unique features. 
Although each strain of mutant mice has unique features. The mdx3Cv mice exhibit 
abnormal breeding behavior and cognitive defects in addition to dystrophic 
muscle pathology. The levels of DAPC proteins and full-length dystrophin were 
decreased. So mdx3Cv mice may act as a useful model for studying the effect of 
subtherapeutic level of dystrophin on DMD phenotype recovery. Surprisingly, 
skeletal muscle strength was only slightly reduced compared to wild type mice and 
muscles were partially protected from eccentric contraction-induced injury [34]. 
Histopathological analysis of skeletal muscles, heart and diaphragm of the mdx4Cv 
and mdx5Cv mutants indicates 10-fold fewer revertants than in the muscles of mdx 
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mice [24]. Also mdx5Cv mice have a more severe skeletal muscle phenotype than 
mdx mice. These mice showed pronounced functional deficits and lower interindi-
vidual variability in motor activity tests compared with mdx mice which is a great 
advantage in studies with small numbers of animals [24, 30, 31]. Both of these 
murine models mdx4Cv and mdx5Cv are currently used in preclinical trials of gene 
therapy [35].
There are several models of mice obtained by crossing mdx mice with other 
genetic backgrounds such as albino mice [36], BALB/c mice, DBA2 mice [37], 
C57BL/6 mice, C3H mice [38], FVB mice and immune deficient mice [24]. In some 
cases background does not dramatically alter dystrophic phenotype of mdx mice 
(BALB/c-mdx mice, C57BL/6-mdx mice, FVB-mdx mice). But some murine models 
obtained during the crossing showed new phenotypic features and more severe 
phenotypes than mdx mice (albino mdx mice, DBA2/mdx mice). For example, 
albino-mdx mice combined signs of muscular dystrophy (histopathology of skel-
etal muscles, increased serum CK level, body and muscle weights) with signs of 
oculocutaneous albinism (skin, fur and eye depigmentation) [36]. In contrast to 
original black mdx mice, albino-mdx mice showed slow geotaxis, which can indi-
cate a deterioration of neurological state of DMD [39], and increased circulating 
cytokines levels [40].
The most phenotypically relevant to the human DMD murine model was cre-
ated on the DBA2 background. The DBA2 inbred mouse strain carries a naturally 
occuring in-frame deletion within the latent TGFβ-Binding Protein 4 (LTBP4) gene. 
This promotes enhanced inflammation and loss of ambulation in DMD patients 
[41]. The DBA2-mdx (D2-mdx) mice showed progressive development of muscular 
dystrophy. These mice had severe histopathological features, including the rapid 
progression of fibrosis in diaphragm and skeletal muscles. In addition, all muscles 
of these mice had zones of extensive calcification. In contrast to original mdx mice 
D2-mdx mice developed cardiomyopathy at an earlier age, moreover, more fibrous 
tissue was observed in the hearts of D2-mdx mice [37]. The more pronounced dys-
trophic phenotype and faster progression of the disease in D2-mdx mice compared 
to mdx mice on C57BL/10 background makes D2-mdx mouse strain more suitable 
for evaluation of treatment efficacy in preclinical trials [42]. Immune-deficient 
mdx mice are used to test cell therapies as one of the approaches to treating mus-
cular dystrophy. These strains were created by crossing of mdx mice with different 
strains of mice with mutations in different genes (c-kit receptor gene, IL-2 receptor 
gene, DNA-dependent protein kinase catalytic subunit deficient and others) and 
deficiency of B cells, T cells and NK cells [43], cytokine signaling deficiency [43], 
hematopoietic cells deficiency [44] or with severe combined immunodeficiency 
[45]. Severity of phenotypical features in immune-deficient dystrophic mice are 
usually similar to mdx mice. But these murine strains are a good model for preclini-
cal trials of cell transplantation therapies.
Mdx murine model lacking dystrophin expression demonstrates less pronounced 
degenerative changes in comparison with DMD in humans. This may be attributed 
to various species-specific compensatory mechanisms in mice, increased expression 
of other membrane proteins in murine muscles, or the characteristics of the skeletal 
and cardiac muscles themselves. To study the effect of compensatory mechanisms 
in mice, double-knockout (DKO) murine models and humanized murine models 
were created. Compensation for the lack of dystrophin with structurally related 
proteins possibly leads to a milder DMD phenotype in mdx mice than in DMD 
patients. In mdx mice, unlike humans, the expression of utrophin, in skeletal 
muscles, diaphragm, heart and non-muscular tissues persists throughout life [46]. 
The amino acid sequence of utrophin repeats largely dystrophin and can hypotheti-
cally substitute it on the sarcolemma and participate in muscle contraction [9].  
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Therefore, upregulation of utrophin may be one of the treatment options for DMD. 
To test such drugs as well as to study DMD pathogenesis, mice deficient in both 
dystrophin and utrophin were created. This double-knockout (mdx/utrn−/−, u-dko) 
murine model was derived from breeding dystrophin deficient mdx mice with 
utrophin deficient mice [47]. In contrast to mdx mice u-dko mice were smaller and 
weaker and developed severe muscular dystrophy phenotype similar to phenotype 
in DMD patients. All clinical signs of the disease (pathohistology of skeletal and 
cardiac muscles, muscle functions) were more pronounced in u-dko mice than in 
mdx mice. These mice also started to show DMD symptoms at an earlier age [47]. 
This murine model is currently used in preclinical trials of gene therapy drugs 
based on adeno-associated or adenoviruses carrying shortened utrophin genes. 
Several studies have shown that utrophin-delivering therapy is equally effective as 
micro/minidystrophin-delivering therapies [48]. Another protein that can replace 
the absent dystrophin and perform complementary function in mdx muscles is the 
membrane protein integrin α7. Dystrophin and integrin α7 double knockout mice 
(mdx/α7−/−), as well as u-dko mice, showed a more apparent dystrophic phenotype 
compared to original mdx mice [49]. Dystrophin- and integrin α7-deficient mice 
had reduced body mass compared to mdx mice and demonstrated early lethality 
(4 weeks after birth). Skeletal and cardiac muscles of double-knockout mdx/α7−/− 
mice were more severely affected and exhibited loss of membrane integrity, more 
prominent histopathological and functional characteristics [49].
Another explanation for the less pronounced dystrophic phenotype in mdx mice 
may be the increased regeneration of muscle fibers after necrosis which presents 
in formation of fibers with centrally located nuclei and muscle pseudohypertrophy 
[23]. To test this hypothesis, several murine models with reduced muscle regenera-
tion were created. Since activated satellite cells are involved in the regeneration 
of skeletal muscle fibers, murine models with knockout of genes involved in the 
activation of satellite cells, were created to limit regenerative capacity. The first 
approach is a knockout of myogenic basic-helix–loop–helix transcription factors 
MyoD which plays an important role in myogenesis [50]. Mice lacking both MyoD 
and dystrophin (mdx/MyoD/−/−) created by breeding of mdx mice with MyoD 
mutant mice developed a severe cardiomyopathy and muscle hypertrophy leading to 
premature death [51]. Phenotypically these mice are much closer to DMD patients. 
The second approach to enhance DMD phenotype in mice is a modeling of the 
telomerase RNA absence. It was established that telomere length in human dystro-
phic cardiomyocytes and skeletal muscles is shorter than in normal muscles [52]. To 
create such a murine model, mdx mice were crossed with mice lacking telomerase 
RNA (mdx/mTR KO) [52]. Mdx/mTR KO showed a severe dystrophic phenotype 
and significantly reduced lifespan compared to mdx or mTR KO controls. Also aged 
mice showed explicit skeletal deformity (kyphosis) [52]. Double knockout mice 
make a significant contribution to the study of DMD pathogenesis and the assess-
ment of DMD drug therapy effectiveness, however, these murine models do not 
directly explain the differences in phenotype between mice and humans. Therefore, 
so-called humanized murine models were created.
Humanization makes phenotype of mdx mice closer to the phenotype of DMD 
patients. Mice have reduced inflammatory and immunologic reactivity com-
pared to humans. For example, mice, unlike humans, evolutionally retained the 
cytidine monophosphate-sialic acid hydroxylase (Cmah) gene. Introduction of 
human-like inactivating deletion of Cmah gene into mdx mice prevented synthe-
sis of the sialic acid N-glycolylneuraminic acid [53]. The mdx/Cmah/−/− mice had 
genotypic and phenotypic similarities to human DMD, enhanced DMD severity 
and shortened lifespan compared to mdx mice. Cardiac muscle of mutant mice 
shows large areas of fibrosis and mononuclear infiltration. These features make 
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mdx/Cmah/−/− murine model suitable for evaluating effects of new DMD therapy 
on dystrophic cardiac muscle.
Dystrophin function, as well as pathogenesis and treatment strategies for DMD 
have been well studied in different murine models (mdx, mdx/Utrn−/− dko and 
many others). All these murine strains lack full-length dystrophin expression and 
show specific dystrophic features. However, the expression of small isoforms of 
dystrophin may remain in some models. To study the contribution of small isoforms 
to the DMD pathogenesis, a model with a completely deleted dystrophin gene 
was created. Using the Cre-loxP recombination system Dmd gene was completely 
removed in mice. The resulting mutants (Dmd-null mice) were viable, but the males 
were sterile. The mice showed an evident dystrophic phenotype and behavioral 
abnormalities [54].
Murine models are the most convenient and widely used for studying protein 
function, pathogenesis and treatment options for the disease. Many preclinical 
trials of drugs that are currently used or tested in clinical trials have been performed 
on DMD murine models. However, many laboratories use not only mice for their 
studies, but also other species of animals, including non-mammalian models, other 
rodents or large mammals. Non-mammalian DMD models were generated in zebraf-
ish Danio rerio, Drosophila melanogaster and Caenorhabditis elegans [24, 30, 31, 55]. 
Non-mammalian DMD models have some advantages over mammals. Fishes, worms 
and insects are eukaryotic models and have some valuable features: small size, 
high reproduction rate, fast growth and development, a large number of offsprings 
and fully sequenced genomes. Dystrophin amino acid sequence and subcellular 
localization are highly conserved between humans and zebrafish. The zebrafish 
dmdta222a mutants (sapje) with dystrophin deficiency showed muscle degenera-
tion which was more severe than in mdx mice and died at an early larval stage [56]. 
Zebrafish DMD model is a good model to test exon-skipping therapeutic strategy. 
For example, FDA approved drug Ataluren (Translarna) was tested on zebrafish and 
led to restoration of muscle contractile functions [57]. One more non-mammalian 
DMD model is dystrophin deficient Drosophila melanogaster. Muscle-specific 
RNAi-mediated knockdown of all dystrophin isoforms in flies led to severe muscle 
degeneration, cardiomyopathy phenotype and climbing deficits [58, 59]. Nematode 
worm Caenorhabditis elegans is also used for DMD model creation. These worms 
have dystrophin homolog gene dys-1. Loss-of-function in dys-1 resulted in worm 
hyperactivity and hypercontraction [55].
In addition to mice, larger animal models are now available. All DMD canine and 
feline models have been identified in natural populations. Porcine, rat, monkey and 
rabbit models were created with CRISPR/Cas9 technology [24, 31]. The most popu-
lar DMD models in large animals are canine models. Spontaneous mutations in the 
dystrophin gene causing the development of dystrophic phenotype have been iden-
tified in 14 dog breeds [60]. Some of them are currently bred in nurseries as a DMD 
canine model, others were discovered in natural populations as individual cases and 
described in the literature. The first group includes the well known golden retriever 
muscular dystrophy dog model (GRMD), Cavalier King Charles spaniel model [61], 
Welsh corgi model Australian Labradoodle model, German short-haired pointer 
and new labrador retriever model with inversion in dystrophin gene [60]. The most 
widely used and well described canine model of DMD is the GRMD model. The 
GRMD mutation was first reported in four animals in the early 1980s [62]. It was 
established that GRMD dogs had a splice site mutation (transition A > G) in intron 
6 causing abnormal mRNA splicing and loss of exon 7 of dystrophin gene. GRMD 
dogs had severe dystrophic phenotype including elevated CK level, skeletal muscle 
atrophy with contractures, dyspnoea, dysphagia, dilated cardiomyopathy, large 
fibrosis and fat tissue areas. The GRMD dog population also showed heterogeneity 
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of dystrophic features between different individuals, what also makes this model 
similar to DMD in humans [60]. A clinical course of GRMD dogs is more similar to 
DMD patients in contrast to mdx mice. Large body size, severe muscular dystrophic 
phenotype, humoral and cellular immune response to viral vector and transgene, 
as well as transplanted cells similar to human, make GRMD dogs a more suitable 
model for preclinical trials to test pharmaceutical drugs, gene replacement therapies 
and cell therapies [31]. The GRMD dogs model was used in different preclinical 
trials of gene and cell therapies. The advantage of using GRMD dogs in these studies 
is the experiment design similar to clinical trials. For example, in clinical trials, the 
inclusion criterion is the intake of immunosuppressive drugs. In dogs, in contrast 
to mice, the immune reactivity is similar to that of humans, which makes it possible 
to reproduce this design as well as to study the obvious adverse reactions associated 
with the activation of host immunity [63]. The mutation of Cavalier King Charles 
spaniel (CKCS) model is a splice site mutation (transition G > T) in intron 50 caus-
ing the deletion of exon 50 [61]. CKCS dogs show elevated levels of serum CK and 
typical areas of necrosis and regeneration in skeletal muscles and heart. Dogs of this 
breed seem to be suitable for testing due to their small body mass and amiable tem-
perament. CKCS canine model can be used to test exon 51 skipping, the therapy that 
may be suitable for many patients, as DMD mutation hotspot is located between 
exons 45 and 55 [61]. The mutation of Welsh corgi model, Australian Labradoodle 
model and German short-haired pointer model (GSHPMD) are LINE-1 insertion 
in intron 13, point mutation in exon 21 and whole DMD gene deletion respectively 
[60]. These dogs show severe dystrophic phenotype including muscle degeneration, 
mineralization and inflammatory infiltration. It is important to note that GSHPMD 
dog model with completely absent dystrophin is the most suitable preclinical model 
for the prediction of immune responses to gene therapy due to the lack of immuno-
logical tolerance to dystrophin [64]. One more interesting canine DMD model is the 
recently identified labrador retriever (LRMD) model with an inversion in dystro-
phin gene. 2.2-Mb spontaneous inversion disrupting the DMD gene within intron 
20 was found in two young labrador retriever dogs. The clinical signs of disease 
included elevated CK level in serum, specific histopathological lesions of skeletal 
and cardiac muscles, myopathic electrodiagnostic profile, high neonatal lethality. 
The LRMD dogs had detected expression of Dp71 isoforms of dystrophin. But 
unlike the GRMD dogs with absent Dp71 isoform, the LRMD dogs have more severe 
dystrophic phenotype. This may indicate that the presence of the Dp71 isoform in 
muscles does not provide a functional advantage [60].
In addition to dystrophic dog colonies maintained in nurseries several cases of 
spontaneous mutations in dogs of different breeds have also been described. The 
interesting case is 7 base pair deletion in exon 42 in Cavalier King Charles spaniel, 
the second CKCS model with mutation in the DMD gene hotspot area. These dogs 
had generalized skeletal muscle atrophy of the temporal region, limbs and thoraco-
lumbar spine [65]. One more case of spontaneous mutation in dystrophin gene was 
revealed in Miniature Poodle dog. Dogs had whole DMD gene deletion and showed 
all dystrophic clinical signs including muscle degeneration, lumbar kyphosis, stiff 
gait and abnormal posture. Neurological examination also revealed reluctance 
to exercise in these dogs [66]. One case of disease development was also recently 
detected in the Jack Russell Terrier population. The dog had deletion of exons 3–21 
causing severe dystrophic phenotype and death at the young age [67]. Progressive 
muscle weakness was also detected in a male border collie dog. Its mutation was a 
single nucleotide deletion in canine DMD exon 20, minor DMD mutation hotspot, 
resulting in generalized muscle atrophy, muscle fatigue and dysphagia [68].
Unequivocally, canine models have a significant advantage over murine models 
due to their more pronounced dystrophic phenotype and possible immune response 
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to treatment. However, as well as mdx mice, GRMD and other dogs have some 
disadvantages associated with the high cost of keeping dog colonies and training 
of personnel caring for sick animals. In addition, due to a greater body weight 
than in mice, large amounts of drugs are required for dogs, which is essential for 
gene therapy based on viral delivery. Nevertheless, studies in dogs are considered 
more informative than studies in mice. The results of the dog trials provide a better 
indication of future clinical trials. In this regard, it is important to use not only 
widespread mice but also dogs in the design of preclinical trials.
The first case of hypertrophic feline muscular dystrophy (HFMD) in domestic 
cats was described in 1989 [69]. Spontaneous mutation causing dystrophic pheno-
type was established as a deletion of the dystrophin promoter and first exons cor-
responding to dystrophin from muscle and Purkinje cells. Dystrophic cats showed 
pronounced appendicular and axial muscle hypertrophy, involving of tongue and 
diaphragm, histopathological lesions in skeletal muscles, diaphragm and heart, 
including different fiber diameter and acute necrosis and cardiomyopathy [70]. The 
HFMD model is rarely used in DMD preclinical research because tongue hyper-
trophy and diaphragm defects lead to difficulties in feeding, animal welfare and 
early death.
The CRISPR/Cas9 technology has made it possible to create several more 
models of DMD in such animals as pigs, rats, rabbits and monkeys. Rats are the 
most convenient animals for biomedical research, therefore several rat models have 
been created. The first rat model was created using CRISPR/Cas9 gene editing [71] 
and had exon 3–6 deleted in dystrophin gene. Dystrophin deficient rats showed 
reduced muscle strength and specific dystrophic phenotype of skeletal muscles, 
diaphragm and heart. Also these rats showed age-dependent decline of cardiac 
functions similar to DMD patients [72]. Later, based on this model, another rat 
model with an in-frame mutation in the dystrophin gene was generated [73]. New 
mutant rats had reduced expression of truncated dystrophin and mild phenotype 
similar to BMD patients. These rats can be useful to study BMD pathogenesis and 
efficiency of dystrophin recovery. The third rat model was created using TALEN 
(Transcription activator-like effector nucleases) technology. Its mutation was a 
frame shifting 11 base pairs deletion in exon 23 generating premature stop codon 
[74]. Animals exhibited reduced muscle strength, cardiomyopathy, large muscle 
necrosis and fibrosis. This model can be used for preclinical research as a small 
DMD animal model.
Several mice models were created that may be suitable mostly for scientific 
use. One of them is the Dmdmdx−bgeo model [75]. It contains the beta-Geo marker 
inserted after exon 63. The protein product translated from the resulting allele 
lacks cysteine-rich and C-terminal domains and is not functional. The Dmdmdx−bgeo 
model mostly resembles the mdx3cv model as both of them lack all dystrophin 
isoforms including Dp71 and Dp40. Hemizygous Dmdmdx−bgeo animals demon-
strate phenotypic properties similar to other mdx models. LacZ (β-galactosidase-
mediated) staining helps to visualize the expression of dystrophin in various 
tissues on different stages of development including embryonic. Nevertheless, the 
dysfunctionality of dystrophin-lacZ chimeric protein should always be taken into 
account.
DmdEGFP reporter mouse [76] lacks the disadvantage of Dmdmdx−bgeo model. The 
eGFP (enhanced green fluorescent protein) coding sequence was introduced behind 
the exon 79 and the chimeric protein remains functional. The transgenic mice did 
not show any signs of pathology. This approach allows us to observe almost all major 
dystrophin isoforms except for those having alternative C-terminal domain. The 
studies with this model may provide valuable data on dystrophin expression and 
localization in muscle and non-muscle tissues and shed the light on its functions.
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In 1999 the Dp71-null mouse model was described [77]. The first and unique 
exon of Dp71 is located between exons 62 and 63 of the Dmd gene. It is replaced by 
promotorless b-geo gene in Dp71-null mice leaving all other dystrophin isoforms 
intact (except for Dp40). The resulting construction provided the expression of 
β-Galactosidase regulated by Dp71 promoter while the native product, Dp71, was 
absent. This model acts as a valuable tool for examination of the role and functions 
of Dp71 isoform both by Dp71 promoter activity estimation by LacZ staining and 
Dp71-null phenotype examination. The further experiments demonstrated that 
Dp71 deficiency causes retinal vascular inflammation, increases retinal vascular 
permeability. AAV-mediated delivery of Dp71 restored retinal homeostasis and pre-
vented retinal oedema [78] and restored defective electroretinographic responses 
[79]. Dp71 expression in neurons plays a regulatory role in synapse organization, 
formation and function and inactivation of Dp71 may lead to increased severity of 
mental retardation and intellectual disability [80].
3. Animal models to test precision medicine approaches
Genetic testing revealed the incredible diversity of mutations in DMD gene. 
However, mutations are not equally presented throughout the gene. As much as 
80% of all mutations are concentrated in exons 2–20 and 45–55 representing two 
hotspots. Mutations can be divided into two groups: frequent (one or more exons 
deletions and duplications) and rare (point substitutions in exons and introns, 
small deletions and duplications). [81]. Mutation-specific precision medicine 
approaches are mostly based on the reading frame rule and convert mutations 
from Duchenne to Becker type. In the presence of frameshift generating mutations 
additional removal of one or several exons can restore the reading frame and cause 
expression of shortened yet functional dystrophin protein. For exons removal 
during splicing process antisense oligonucleotides (ASO, AON) are used. AON 
binds specifically to the splice sites of selected exons hiding them from cellular 
splicing machinery and leading to their exclusion from mRNA. Different chemical 
structures are used for reduced AON cleavage, prolonged circulation, better cellular 
and nuclear penetration. The most popular backbones are presented by PMO 
(phosphorodiamidate morpholino oligomers), 2-OMePS (2’O-methylated phospho-
rothioate), vivo-morpholino (morpholino oligo covalently linked to octaguanidine 
dendrimer), LNA (locked nucleic acids), tcDNA (tricyclo-DNA). Indeed, AON 
can be delivered naked or in the lipid complex, fused with targeting peptides or 
other molecules enhancing biodistribution. In addition to AON, vectorized drug 
candidates are tested for exon skipping. Their design is based on U7 snRNA, 
naturally participating in histone pre-mRNA processing. Deletion of additional 
exons directly from genomic DNA (gDNA) is also proposed as a mutation-specific 
therapeutic strategy for DMD. For this purpose viral delivery of one or two single 
guide RNA (sgRNA) and Cas9 encoding sequences is tested. Targeted Cas9-induced 
double strand cleavage is also applied for indel generation in affected or neighbor-
hood exons. Indels lead to +1 or − 1 frameshifts with a certain probability. This 
approach is known as reframing. Exon can be excluded from mRNA due to another 
DNA modification - base editing in conservative splice site sequence. For this 
approach Cas9 fused with base editing enzymes is utilized. Both for U7 snRNA (U7 
small nuclear RNA) and Cas9 delivery viral vectors such as lentiviruses and AAV 
are used. Majority of experiments for mutation-specific approach examinations are 
conducted on patients-derived cell cultures and modified human embryonic stem 
(ES) cells. However, complexity of the disease and limitations of functional tests 
applicable in vitro force to generate and use genetically modified animal models. 
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Mice with various mutations in the dystrophin gene, replicating mutations found in 
individual patients or groups of patients are the most common among the genome-
edited models. The timeline of disease progression and traits of new models are 
usually not well studied. Main DMD symptoms are similar to those found in mdx 
mice. The purpose of these “genetic” models is to test mutation-specific therapies 
and show not only restoration of dystrophin expression but also improvement in 
locomotor activity, illustrating the functionality of the shortened protein. The ease 
of maintenance and reproduction, extensive experience in obtaining and speed of 
reproduction, together with the high conservativeness of the dystrophin gene, make 
mice the optimal objects for such work, nevertheless, there are other, larger animal 
models with mutations often found in patients with DMD.
Deletions of one or more exons are the most common mutations in the DMD 
gene. They account for 68% of all mutations. Among them, deletions of single exon 
44 (3%), 45 (4%), 50 (2%), 51 (3%), 52 (3%) are represented with approximately 
the same frequency [81]. Directed mutations in the dystrophin gene in labora-
tory animals were obtained for the purpose of selecting drugs for exon-skipping. 
Exon structures of popular models with deletions in mutation hotspot are shown 
on Figure 1. The first models were obtained by homologous recombination using 
embryonic stem cells. In 1997 a mouse model mdx52 with a deletion of exon 52 was 
created [82], where this exon was replaced with a neomycin resistance cassette. 
This mouse model was used to test various drug candidates: PS-modified tcDNA 
(phosphorothioate-modified Tricyclo-DNA) based ASO for skipping of the exon 51 
[83], PMO for exon 51 skipping [84, 85], AAV9-U7snRNA for exon 51 skipping [86], 
Figure 1. 
Animal models representing DMD exon deletions in mutation hotspot. Gene fragment structures around exon 
with frameshift mutation are shown on the left. Currently tested therapeutic approaches and resulting exon 
structures are shown on the right.
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mix of vivo-morpholinos for simultaneous skipping of the exons 45–55 [87, 88]. 
With the advent of effective genome editing techniques, frequent mutations were 
the first to be reproduced in animals. TALEN were used to create mice with exon 
52 deletion resulting in del52hdmd/mdx model [89]. This model is notable for the 
fact that the mutation was introduced into the sequence of the human gene. Thus, 
del52hdmd/mdx model can be used to test drugs that are designed to target unique 
human sequences. The authors showed the effectiveness of AON for skipping exons 
51 and 53 to the human sequence during intramuscular delivery [89]. This line was 
used to test CRISPR/Cas9 genome editing complexes for reframing in exons 51 
and 53 during lentiviral delivery [90]. AAV9 double SaCas9 (Staphylococcus aureus 
Cas9 ortholog) and guide mix was tested for deletion with borders within exons 
47 and 58 for himeric exon formation [91]. Later, another mouse model with a 
deletion of exon 52, ∆52, was obtained using CRISPR/Cas9 genome editing system 
[92]. This model was used to test CRISPR/Cas9-based drugs for exon 53 removal 
or reframing [92].
Reframing in exon 51 was also tested in mouse models with deletion of exon 50 
ΔEx50 and ΔEx50-Dmd-Luc [93]. In the Dmd gene of ΔEx50-Dmd-Luc mice, in 
addition to the deletion of exon 50, the luciferase gene sequence is also introduced 
at the C-terminus, connected to the protein sequence via an autocatalytic 2A pep-
tide. Thus, luminescence was observed during the restoration of the reading frame, 
which allowed to assess the effectiveness of drugs in vivo without resorting to 
invasive methods [93]. Bioluminescence was detected both after intramuscular and 
systemic delivery of Cas9 and sgRNA-51 by AAV9. The presence of bioluminescence 
was shown to correlate with dystrophin expression as verified by western blotting 
and immunohistochemistry (IHC) [93].
One of the most frequent deletions, the deletion of exon 44, was reproduced in 
mice Δex44 DMD [94]. Correction of exon 44 deletions by gene editing of sur-
rounding exons could potentially restore the reading frame of dystrophin in ~12% 
of patients with DMD. Authors created AAV9-Cas9 and AAV9-sgRNA mix targeting 
5′-end of exon 45 and tested them in vivo during intramuscular injections on this 
model. The most perspective guide sequence 6 (G6) was used for systemic delivery 
and selection of a better Cas9 to sgRNA AAV particles ratio. Selected conditions lead 
to force increase from 59% to 107% in the extensor digitorum longus (EDL) muscle 
of ΔEx44 DMD mice [94]. 20-fold lower dose of self-complementary adeno-
associated virus (scAAV) bearing Cas9 + sgRNA was used for exon 45 skipping and 
reframing on the same model [95]. Weekly injection of (1,2-dioleoyl-3-trimethyl-
ammonium-propane) LNPs (lipid nanoparticles) encapsulating Cas9/sgDMD RNPs 
(ribonucleoproteins) into Tibialis Anterior (TA) muscles was tested on ΔEx44 
DMD mice. The expression of dystrophin in TA muscles was successfully restored 
after skipping or reframing of exon 45 induced by treatment, as demonstrated by 
immunofluorescence and western blot analysis. Quantitative analysis of the western 
blot result showed that 4.2% of dystrophin protein was restored [96].
CRISPR/Cas9 genome edited hDMD del45 model represents deletion of exon 
45 in human dystrophin gene in the presence of wild type Dmd gene while hDMD 
del45 mdx D2 has dystrophic phenotype due to Dmd gene knock-out [97]. In the 
same paper exons 45–55 deletion strategy (Cas9 + gRNAs to introns 44 and 55) 
aiming to help 60–65% of patients was tested [97, 98]. A more realistic approach 
from the clinical application point of view is multiple exon 45–55 skipping using U7 
snRNAs [99]. It was tested on hDMD/mdx model [100]. Similar multiple exon-
skipping strategy using PMOs cocktail [98] was tested on hDMD/Dmd Null mice 
[85]. The hDMD/Dmd Null model compares favorably with the previous models, 
since it does not have a mouse dystrophin sequence and allows us to quantify the 
level of exon skipping and compare the effectiveness of different sequences and 
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drugs with each other, which is demonstrated by the example of exon 51 skipping 
[85]. Moreover, the presence of normal dystrophin in some models leads to the 
absence of the necessary symptoms for the delivery of oligonucleotides and viruses, 
such as inflammation in the muscles and intact cellular membranes. It’s necessary 
to point out the crucial role of hDMD mouse model with full-length DMD gene 
integrated into chromosome 5 [100]. It is not very useful for any drug substances by 
itself due to simultaneous expression of wild type human and murine dystrophin 
proteins. But when crossing to mdx or other Dmd knockout mice (hDMD/mdx, 
hDMD/Dmd Null) it becomes an extremely important background for creation of 
new models. Any antisense or guide molecules designed and tested on subsequent 
animals can be transferred to human cells without sequence adaptation.
Models with single exon deletions ∆43 (exon 43 deletion), ∆45 (exon 45 dele-
tion) were reported together with ∆52 (exon 52 deletion) DMD mice [92]. These 
mouse models were used to test single guide genome editing procedures aiming 
at exon skipping or reframing. AAV9 and scAAV9 viruses with a guide and Cas9 
sequences were used. Intramuscular delivery of guide RNA to exon 44 and Cas9 
encoding viruses to TA muscle restored dystrophin expression in both ∆43 and ∆45 
DMD models. Interestingly, the selected guide generated both exon reframed and 
exon skipped transcripts in ∆45 DMD muscle, but only exon skipped transcripts in 
∆43 DMD muscle. Restoration of dystrophin in ∆45 DMD muscle was more effi-
cient than in ∆43 DMD muscle when using the same sgRNA for gene editing [92].
Deletions of several exons are quite common in patients, but to date only one 
mouse model with an extended mutation in the hotspot is known. Deletion of 
exons 52–54 was simulated in Dmd Δ52–54 in which authors declare severe cardiac 
dysfunction in addition to common skeletal muscle symptoms. CRISPR-mediated 
single sgRNA exon skipping of exon 55 was tested on this model. Also another 
model with deletion of exons 52–55 was created to check potential benefit of the 
treatment [101]. CRISPR/Cas9 system popularity, easy to use and high efficiency 
allow to generate such 100% skipping (editing) models to check generated short-
ened dystrophin protein functionality.
Duplications of one or several exons are also highly widespread mutations, 
affecting 5–10% of all DMD patients [102]. The most common duplication in the 
patient population Dup2 (duplication of exon 2) was recreated in the mouse model 
created in 2015 [103]. Correction of the mutation was shown on this model after 
intramuscular injections of AAV1.U7-ACCA [104]. Main attribute of this mutation 
and corresponding model is that precision skipping of a duplicated exon results 
in full-length dystrophin expression. Thus, it is the rare case when exon-skipping 
converts Duchenne type mutation to wild type rather than Becker type. At the same 
time it is a challenge to accurately skip only copy of exon 2 not affecting the main 
sequence.
Nonsense mutations are also very common in the human population affecting 
approximately 25% of the patients [102]. The most popular mdx mouse model 
representing nonsense mutation was found in the natural population [105]. A lot 
of treatment strategies targeting downstream disease mechanisms were tested 
on this model. Precision medicine approach on mdx model includes stop codon 
readthrough [106]. Targeted single nucleotide mutation was created in DMD-KO 
(D108) mouse [107] representing C-to-T conversion generating stop codon in exon 
20 (Q871Stop). This mouse model was used for adenine base editing using guided 
SpCas9 (Streptococcus pyogenes Cas9 ortholog) nickase [108]. Created by ENU muta-
genesis, mdx4cv model also has C-to-T conversion in exon 53 generating TAA stop 
codon [33]. Adenine base editor was also tested on this mouse model with modified 
Cas9 recognizing relaxed minimal PAM (protospacer adjacent motif) sequence 
- NG [109]. Both mdx and mdx4cv models were used for trans-splicing method 
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efficiency demonstration [110]. Intramuscular delivery of AAV vectors expressing 
trans-splicing template (PTM) allowed detectable levels of dystrophin in mdx and 
mdx4cv, illustrating that a given PTM can be suitable for a variety of mutations.
Rare mutations found in patients were repeated in models to test precision 
gene editing methods. Those contain big deletion of exons 8–34 in DmdDel8–34 
mouse model (Egorova et al., 2019). Reading frame in this model can be restored 
by simultaneous skipping of exons 6 and 7. The fact that the N-terminal actin 
binding domain is partly encoded by these exons, gives the opportunity to better 
understand structure-functional interplay in dystrophin protein and its shortened 
forms. Several approaches including vivo-morpholino induced exon-skipping and 
CRISPR/Cas9 gene editing are tested on this model ([111]; unpublished data). 
Other variants of rare mutations generated by Koo and colleagues, represent small 
frameshift mutations [112]. In vivo treatment with AAV vectors encoding CjCas9 
(Campylobacter jejuni Cas9 ortholog) and single guide to the affected exon restored 
the reading frame and enhanced muscle strength.
Large mammalian models have more pronounced DMD symptoms in compari-
son to murine models. But limited availability and less extensive experience in their 
genome modification led to reduced use in precision medicine approaches testing. 
Pig model with deletion of exon 52 DMDΔ52 was created using somatic nuclear 
transfer from bacterial artificial chromosome (BAC)-edited cells [113]. AAV9 vector 
with intein splitted Cas9 and two guides around exon 51 was tested on these animals 
reaching widespread dystrophin expression, prolonged survival and reduced 
arrhythmogenic vulnerability [114]. Another example of CRISPR/Cas9 Dmd gene 
targeting in pigs resulted in indels in exon 27 which lead to premature piglet death 
at day 52 [115]. So this model was not tested yet for any treatment approach.
DMD KO rabbits represent different mutations in exon 51 which is within the 
mutation hotspot in human DMD gene [116]. Many of these mutations are small 
deletions or insertions, disrupting the reading frame of the DMD gene, resulting in 
frameshift and complete absence of dystrophin expression followed by main pheno-
typic features in skeletal muscles and cardiomyopathy. Animals could benefit from 
50–51, 51–52 or 45–55 exons skipping, however this model animals were not used for 
any precision medicines testing.
Identified in natural population CKCS-MD (deltaE50-MD) dogs have a splice 
site missense mutation in intron 50 of the DMD gene, causing out-of-frame skip-
ping of exon 50 and resulting in a lack of dystrophin and a severe dystrophic 
phenotype resembling DMD [61]. In the same paper authors show that additional 
skipping of exon 51 could restore dystrophin expression on cultured myoblasts [61]. 
Single guide genome editing aiming at exon 51 skipping or reframing shows big 
potential after intramuscular and intravenous delivery [117].
Naturally occurring intron splice site mutation that leads to the loss of exon 7 
was identified in Golden retriever dogs leading to generation of GRMD (CXMDJ) 
canine model [62]. It is the most widespread canine model which is used in numerous 
studies including exons 6 and 8 skipping driven by PMO and 2’OMePS [118, 119], 
AAV1-U7snRNA [120], rAAV6-U7snRNA [121], AAV8-U7snRNA [122].
The next model stands out and its value is more in demonstrating the possibility 
of creating new models than in itself. The new mice obtained by transgenesis carry 
randomly embedded copies of the EGFP under the CAG promoter (strong syn-
thetic promoter that consists of regulatory elements from CMV, chicken beta-actin 
gene and rabbit beta-globin gene), which are separated by exon 23 with the murine 
mdx mutation. EGFP expression is possible only in case of exon 23 skipping, which 
was demonstrated using PMO and LNA/2’-OMe based AONs [123]. Thus, the 
resulting mouse model allows noninvasive assessment of the effectiveness of exon 
skipping, as well as studying the bio-distribution of drugs. The creation of similar 
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mouse models for testing exon skipping, more applicable to patients, will allow 
more intensive studies of future drugs.
4. Conclusions
Here we described several dozens of Duchenne muscular dystrophy models. 
The list of species used to create these models includes worms, fruit flies, fishes, 
dogs, cats, mice, pigs, rats and monkeys. Some of them were found in natural 
populations, while the others were artificially created. The spectrum of genetic 
interventions spans from point mutations to complete deletion of the largest gene 
- Dmd gene, double knockouts and humanized constructions. The genetic and 
phenotypic diversity provides great opportunities for fundamental studies and drug 
development.
The correspondence of the model phenotype to human DMD phenotype is 
extremely important for drug testing. Some of the models, especially based on 
small animal species, could not represent DMD features correctly. The same goes 
for many mice models. The mouse model which has mutation identical to a certain 
DMD case may not correctly represent the DMD phenotype. Vice versa, several 
double knockout mice models reproduce the DMD phenotype much closer while 
being an inadequate genetic model. The models based on larger species are more 
useful as their phenotype is usually closer to DMD. But the creation, maintenance 
and cost of these animals complicates their use and restricts diversity. Indeed, no 
ideal DMD model is still created. However, the development of novel promising 
DMD treatment strategies requires both genetically similar models for precision 
drugs testing and phenotypically appropriate models for disease study and design 
of therapies. We should expect the expansion of the DMD-related animal models 
list in the nearest future.
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